The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Treatment for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping following prior treatment with immunotherapy and/or platinum-based ChT
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
VISION
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Cemiplimab
-
Platinum based ChT (Crossover allowed)
First-line unresectable
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1>50% negative EGFR, ALK or ROS1
EMPOWER-Lung 1
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Cabozantinib
-
Sunitinib
First-line treatment of adult patients with intermediate or poor risk advanced RCC
Genitourinary Cancers
Renal cell cancer
-
CABOSUN
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Dostarlimab
-
Single arm (Phase I)
Treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that have progressed on or following prior treatment with a platinum-containing regimen
Gynaecological Malignancies
Endometrial Cancer
dMMR or MSI-H
GARNET
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Nivo/Ipi (nivolumab and ipilimumab)
2 cycles of platinum-based ChT
Chemotherapy
First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CheckMate-9LA
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
5-FU/LV (5-fluorouracil + leucovorin)
-
Lomustine (MeCCNU) + vincristine + 5-FU
Patients with Dukes' stage B and C colon cancer
Gastrointestinal Cancers
Colon Cancer
-
NSABP C-03
A
ADJUSTMENTS
FINAL SCORE
F1
1
5-FU (fluorouracil)
Folinic acid
Observation
Patients with surgically resected colon cancer in Dukes' stage C
Gastrointestinal Cancers
Colon Cancer
-
-
A
ADJUSTMENTS
FINAL SCORE
F1
1
5-FU/LV (fluorouracil + leucovorin)
-
Observation
High-risk stage II or stage III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
NCCTG 874651
A
ADJUSTMENTS
FINAL SCORE
F1
1
5-FU (fluorouracil)
Folinic acid
Surgery alone
Patients with resectable Dukes B and C (AJCC/UICC Stage II and Stage III) colon carcinoma
Gastrointestinal Cancers
Colon Cancer
-
GIVIO-SITAC 01
A
ADJUSTMENTS
FINAL SCORE
F1
1
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with stage II and III colon cancer (ITT and age stratified including >70 years)
Gastrointestinal Cancers
Colon Cancer
-
-
A
ADJUSTMENTS
FINAL SCORE
F1
1
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.